Study on Platelet Adhesion and Aggregation Induced by Gradient Shear Stress Using Microfluidic Chip Technology / 中国实验血液学杂志

OBJECTIVE@#To study the effect of gradient shear stress on platelet aggregation by microfluidic chip Technology.@*METHODS@#Microfluidic chip was used to simulate 80% fixed stenotic microchannel, and the hydrodynamic behavior of the stenotic microchannel model was analyzed by the finite element analysis module of sollidwork software. Microfluidic chip was used to analyze the adhesion and aggregation behavior of platelets in patients with different diseases, and flow cytometry was used to detect expression of the platelet activation marker CD62p. Aspirin, Tirofiban and protocatechuic acid were used to treat the blood, and the adhesion and aggregation of platelets were observed by fluorescence microscope.@*RESULTS@#The gradient fluid shear rate produced by the stenosis model of microfluidic chip could induce platelet aggregation, and the degree of platelet adhesion and aggregation increased with the increase of shear rate within a certain range of shear rate. The effect of platelet aggregation in patients with arterial thrombotic diseases were significantly higher than normal group (P<0.05), and the effect of platelet aggregation in patients with myelodysplastic disease was lower than normal group (P<0.05).@*CONCLUSION@#The microfluidic chip analysis technology can accurately analyze and evaluate the platelet adhesion and aggregation effects of various thrombotic diseases unde the environment of the shear rate, and is helpful for auxiliary diagnosis of clinical thrombotic diseases.

Low triiodothyronine syndrome is associated with platelet function in patients with nephrotic syndrome

SUMMARY OBJECTIVE The objective of this study was to investigate the effects of low triiodothyronine syndrome (LT3S) on platelet function and clotting factors in patients with nephrotic syndrome(NS). METHODS Patients with primary nephrotic syndrome were divided into two groups, normal thyroid function (group A) and LT3S (group B), based on whether they had LT3S or not. Healthy subjects were selected as the control group (group C). Blood coagulation function was detected in each group. The platelet activation function (CD62P, CD63) was determined by flow cytometry. The platelet aggregation rate was detected by an optical method using adenosine diphosphate and arachidonic acid as inducers. RESULTS The proportion of primary nephrotic syndrome with LT3S was 23.2% (69/298). Compared with group C, group A had higher CD62P and PAgTADP, and group B had higher CD62P, CD63, PAgTAA, and PAgTADP; the difference was statistically significant (all P < 0.05). There was no significant difference in renal pathology between group A and group B (X2 = 4.957, P = 0.421). Compared with group A, the 24-hour urine protein, CD63, PAgTAA, and PAgTADP were higher in group B, and APTT and Alb were lower. The difference was statistically significant (P < 0.05). Logistic regression analysis showed that LT3S was associated with CD36 (OR: 3.516; 95% CI: 1.742~8.186; P = 0.004) and PAgTAA (OR: 0.442; 95% CI: 1.001~1.251; P = 0.037). CONCLUSION NS patients are prone to LT3S. Patients with LT3S may have abnormal platelet activation and increase of platelet aggregation.

RESUMO OBJETIVO O objetivo deste estudo foi investigar os efeitos da síndrome do baixo triiodotironina (LT3S) na função plaquetária e nos fatores de coagulação em pacientes com síndrome nefrótica (SN). MÉTODOS Pacientes com síndrome nefrótica primária foram divididos em dois grupos, função tireoidiana normal (grupo A) e LT3S (grupo B), com base na presença ou não de LT3S. Indivíduos saudáveis foram selecionados como grupo de controle (grupo C). A função de coagulação do sangue foi analisada em cada grupo. A função de ativação plaquetária (CD62P, CD63) foi determinada por citometria de fluxo. A taxa de agregação plaquetária foi detectada por um método óptico usando adenosina difosfato e ácido araquidônico como indutores. RESULTADOS A proporção de síndrome nefrótica primária com LT3S foi de 23,2% (69/298). Em comparação com o grupo C, o grupo A apresentou níveis mais altos de CD62P e PAgTADP, e o grupo B apresentou maiores CD62P, CD63, PAgTAA e PAgTADP; a diferença teve significância estatística (P < 0,05). Não houve diferença significativa na patologia renal entre o grupo A e o grupo B (X2 = 4,957, P = 0,421). Em comparação com o grupo A, a proteína em urina de 24 horas, CD63, PAgTAA e PAgTADP foram maiores no grupo B, já APTT e Alb foram mais baixos. A diferença apresentou significância estatística (P < 0,05). A análise de regressão logística mostrou uma associação entre LT3S e CD36 (OR: 3,516; 95% IC: 1,742~8,186; P = 0,004) e PAgTAA (OR: 0,442; 95% IC: 1,001~1,251; P = 0,037). CONCLUSÃO Pacientes com síndrome nefrótica estão propensos à síndrome do baixo triiodotironina (LT3S). Pacientes com LT3S podem ter ativação plaquetária anormal e aumento da agregação plaquetária.

NADPH oxidasa: rol en aterosclerosis y función plaquetaria / NADPH OXIDASE: role in atherosclerosis and platelet function

Reactive oxygen species have emerged as important molecules in cardiovascular function. Recent research has shown that the NADPH oxidases are important sources of superoxide in vascular cells and myocytes. The NADPH oxidases vascular share some, but not all, of the characteristics of the enzyme in neutrophils, both produce superoxide, which is metabolized to hydrogen peroxide, at the same time these reactive oxygen species serve as second messengers activate multiple intracellular signalling pathways. NADPH oxidases are essential in the physiological response of vascular cellsto pathological states such as atherosclerosis, and are functionally relevant in activation and recruitment of platelets. Recent studies suggest a key role for NADPH oxidase in the formation of a specific product from the oxidation of arachidonic acid, and a potential role in the process of recruitment of platelets. Taking into account these characteristics and evidence of the involvement of the NADPH oxidases in cardiovascular diseases as the thrombosis, inhibition of this enzymatic system appears as a promising therapy to treat and prevent these diseases.

Participação das plaquetas no processo de fibrose dos pacientes com esquistossomose mansônica / Participation of platelets in the process of fibrosis in patients with mansonic schistosomiasis

O objetivo deste estudo foi avaliar a ativação plaquetária através da P-selectina e o conteúdo de PDGF-AB e TGFbeta1, nos pacientes com esquistossomose que desenvolveram fibrose (F3), naqueles que não tiveram esta manifestação (F0) e nos controles (C). Os resultados mostraram que a percentagem de P-selectina nas plaquetas sem estímulo de agonistas foi de 10,6 por cento nos F3; 11,1 por cento nos FO, e 6,3 por cento nos C e após a adição de ADP/adrenalina, foi de 44 por cento; 25,3 por cento e 42 por cento, respectivamente. A dosagem do PDGF-AB e TGFbeta1 por plaquetas foi de 11,016ng/dL (F3); 3,172 ng/dL (F0) e 5,01ng/dL (C) e, (0,012ng/dL (F3); 5,27ng/dL (F0) e 4,66ng/dL (C), respectivamente. Em relação à P-selectina, concluímos que as plaquetas dos pacientes com esquistossomoses, apesar de estarem pré ativadas, mantiveram-se responsivas aos agonistas. O TFGbeta1 não apresentou diferença entre os três grupos, enquanto o PDGF-AB foi significantemente maior no grupo F3, sugerindo a participação deste no desenvolvimento da fibrose.

The aim of this study was to evaluate platelet activation through P-selectin, and PDGF-AB and TGFbeta1 content, in schistosomiasis patients who developed fibrosis (F3) and who did not present this (F0), and in a control group (C). The results showed that the percentage of P-selectin in platelets without agonist stimulation was 10.6 percent in F3, 11.1 percent in F0 and 6.3 percent in C. After the addition of ADP/adrenaline, the percentages were 44 percent, 25.3 percent and 42 percent, respectively. The PDGF-AB and TGFbeta1 contents per platelet were 11,016ng/dl (F3), 3,172ng/dl (F0) and 5.01ng/dl (C) and 0,012ng/dl (F3), 5.27ng/dl (F0) and 4.66ng/dl (C), respectively. Concerning the P-selectin, we can conclude that platelets from patients with schistosomiasis continued to be responsive to agonists, despite being pre-activated. There were no differences in TGFbeta1 between the groups, but the PDGF-AB content was significantly higher in F3. This suggests that PDGF-AB may have some participation in the development of fibrosis.

Platelet concentration of plateletrich plasma from dogs, obtained through three centrifugation speeds

The platelets release at least 4 growth factors (Platelet Derived Growth Factor. â1 and â2 Transforming Growth Factors and Insulin-like Growth Factor) which are responsible for the migration and activation of cells that will start the reparation of soft tissues and bones. The Platelet Rich Plasma is an autogenous source for Growth Factors, obtained by platelet concentration by centrifuging total blood. This study aimed the comparison of platelet concentrations in plasma centrifuged in three different centrifugation speeds (1300, 1600 e 3200rpm), for the production of platelet rich plasma. Blood was drowned from 15 dogs, 40ml of each, and these were divided into four groups and centrifuged at 800rpm. Then the first group was centrifuged at 1300rpm, the second at 1600rpm, the third at 3200rpm and the last was used as control, named plasma. The mean percentage increase in the platelet concentration for each technique was: 1300 –183%, 1600 – 210% and 3200 – 222%. But in centrifugation at 3200rpm, platelets presented altered morphology and different sizes in every sample studied, which was understood as severe cell damage. It was concluded that the best technique for the preparation of the platelet rich plasma in dogs consisted of the previous centrifugation of the blood at 800rpm for ten minutes, and then the plasma should be separated. This plasma is then submitted to a second centrifugation of 1600rpm for 10 minutes, and the platelet poor plasma is separated and discharged.

Plaquetas liberam ao menos quatro fatores de crescimento ( Fator de Crescimento derivado de Plaquetas, Fatores de transformação de crescimento â1 and â2 e Fator de crescimento semelhante a insulina) responsáveis pela migração e ativação de células que iniciarão os processos de reparação de tecidos moles e ossos. O Plasma Rico em Plaquetas é fonte autógena de fatores de crescimento, obtida pela concentração das plaquetas através de centrifugação de sangue total. Este estudo visa a comparação das concentrações plaquetárias no plasma obtidas por três diferentes velocidades de centrifugação (1300,1600 e 3200 rpm), para produção de Plasma Rico em Plaquetas. 40 ml de sangue total foram retirados de cada animal, divididos em quatro grupos, e centrifugados inicialmente a 800 rpm. A seguir, as amostras do primeiro grupo foram centrifugadas a 1300 rpm, as do Segundo a 1600 rpm, as do terceiro a 3200 rpm e as do quarto grupo foram usadas como controle, denominadas plasma. O aumento médio da porcentagem na concentração de plaquetas para cada técnica foi: 1300- 183%, 1600 - 210% e 3200 - 222%. No entanto, a centrifugação a 3200 rpm, as plaquetas apresentaram a morfologia alterada e tamanhos diferentes em cada amostra estudada, que foram compreendidas como danos celulares severos. Como conclusão deste estudo, obteve-se que a melhor técnica para a preparação do plasma rico em plaquetas de cães consiste na centrifugação precedente do sangue em 800 rpm por dez minutos, separando o plasma, sendo este submetido a uma segunda centrifugação de 1600 rpm por 10 minutos, separando e desprezando o plasma pobre em plaquetas.

Filamina plaquetaria: una proteína del citoesqueleto integradora de la función celular / Platelet filamin: a cytoskeletal protein involved in cell signal integration and function

Activation of cellular receptors by diverse stimuli induces dramatic changes in shape and function to respond to the new circumstances of the cell. This modified behavior depends on the reorganization of the peripheral actin meshwork. An outstanding example of these processes can be found in platelets, from which much of the information available on cytoskeletal function has been obtained. Among the many actin-crosslinking proteins like spectrin, fimbrin or alpha actinin, filamin a (FLNa) emerges as the one with the highest potential in initiating the polimerization of actin filaments (F-actin) during the formation of tridimensional actin gels. FLNa also links actin filaments to the cytosolic domain of many membrane glycoproteins in platelets through its C-terminal region. In addition to participating in cell shape changes, FLNa is a scaffoldding protein that recruits numerous proteins involved in a completely different set of functions, including signal transduction, gene transcription regulation, and receptor translocation; however, the physiological role of FLNa in these processes has remained elusive. The purpose of the present communication is to briefly describe the characteristics of the macromolecules able to interact with FLNa and to discuss a possible role of FLNa during the transduction of signals from those molecular elements in platelets.

Ativação plaquetária em formas clínicas distintas da doença arterial coronariana (papel da P-selectina e de outros marcadores nas anginas estável e instável) / Platelet activation in different clinical forms of the coronary artery disease (roll of P-selectin and others platelet markers in the stable and unstable angina) / Platelet activation in different clinical forms of the coronary artery disease (roll of P-selectin and others platelet markers in the stable and unstable angina)

OBJETIVO: Os marcadores da ativação plaquetária em geral se apresentam elevados na doença arterial coronariana. Desse modo, procuramos identificar a presença e as potenciais associações de diferentes marcadores da ativação plaquetária. MÉTODOS: Estudamos pacientes com angina instável (n=28), pacientes com angina estável (n=36) e pacientes sem doença arterial coronariana (n=30); sexo e idade foram estratificados. Os níveis sangüíneos da molécula de adesão P-selectina, do thromboxane B2 e de serotonina foram medidos por imunoensaios enzimáticos. RESULTADOS: Quando comparamos os grupos, os resultados foram: a P-selectina, o thromboxane B2 e os níveis do serotonina apresentaram-se significativamente mais elevados nos pacientes com angina instável do que nos pacientes com angina estável. CONCLUSÃO: Estes marcadores da ativação plaquetária podem, portanto, identificar formas instáveis de doença arterial coronariana.

OBJECTIVE: Markers of platelet activation are elevated in coronary artery disease. We sought to identify the presence and the potential associations of different markers of platelet activation. METHODS: We studied patients with unstable angina (n=28), patients with stable angina (n=36) and patients without coronary artery disease (n=30); sex and age matched. Blood levels of the adhesion molecule P-selectin, Thromboxane B2 and Serotonin were measured by enzyme immunoassays. RESULTS: When we compared the groups the results were: sP-selectin, thromboxane B2 and serotonin levels were significantly higher in patients with unstable angina than in patients with stable angina. CONCLUSION: These markers of platelet activation were able to identify unstable forms of coronary artery disease.

La citometría de flujo en el estudio de las plaquetas / Flow cytometry in the study of platelets

En la década de los 60 comenzó a desarrollarse la técnica de citometría de flujo, pero los primeros trabajos basados en esta técnica aplicados al estudio de las plaquetas, aparecieron a finales de la década de los 80 del siglo pasado. Los ensayos de citometría de flujo complementan e incluso pueden remplazar los estudios convencionales de función plaquetaria. Se describen las ventajas y limitaciones del método, así como los antígenos plaquetarios que más se han empleado como marcadores de activación plaquetaria. El valor diagnóstico del método ha sido bien establecido en el estudio de defectos genéticos, de los síndromes protrombóticos que involucran activación plaquetaria, trombopoyesis, terapia antitrombótica, estudios de trombocitopenias alo y autoinmunes, así como la activación plaquetaria en otras situaciones clínicas como el infarto agudo de miocardio y la angina inestable. La incorporación de la citometría de flujo al estudio de las plaquetas ha tenido una importante repercusión no solo en el diagnóstico, sino también en la fisiopatología de un grupo de enfermedades relacionadas con el comportamiento plaquetario

Activated platelets induce secretion of interleukin-1beta, monocyte chemotactic protein-1, and macrophage inflammatory protein-1alpha and surface expression of intercellular adhesion molecule-1 on cultured endothelial cells

Atherosclerosis is an inflammatory disease. Platelet-endothelium interaction plays an important role in the pathophysiology of atherogenesis. We investigated the role of activated platelets for secretion of interleukin (IL)-1beta, monocyte chemotactic protein (MCP)-1 and macrophage inflammatory protein (MIP)-1alpha and expression of intercellular adhesion molecule (ICAM)-1 on endothelial cells. Human umbilical vein endothelial cells (HUVEC) were incubated with non-stimulated or ADP-activated platelets for 6 hr. Secretion of interleukin (IL)-1beta, MCP-1 and MIP-1alpha and surface expression of ICAM-1 were measured by ELISA and flow cytometry. In the presence of activated platelets, the secretion of IL-1beta, MCP-1, and MIP-1alpha and surface expression of ICAM-1 were significantly increased compared with non-activated platelets. The present study shows that activated platelets may contribute to expression of various inflammatory mediators on endothelial cells.

Activated platelets induce secretion of interleukin-1beta, monocyte chemotactic protein-1, and macrophage inflammatory protein-1alpha and surface expression of intercellular adhesion molecule-1 on cultured endothelial cells

Atherosclerosis is an inflammatory disease. Platelet-endothelium interaction plays an important role in the pathophysiology of atherogenesis. We investigated the role of activated platelets for secretion of interleukin (IL)-1beta, monocyte chemotactic protein (MCP)-1 and macrophage inflammatory protein (MIP)-1alpha and expression of intercellular adhesion molecule (ICAM)-1 on endothelial cells. Human umbilical vein endothelial cells (HUVEC) were incubated with non-stimulated or ADP-activated platelets for 6 hr. Secretion of interleukin (IL)-1beta, MCP-1 and MIP-1alpha and surface expression of ICAM-1 were measured by ELISA and flow cytometry. In the presence of activated platelets, the secretion of IL-1beta, MCP-1, and MIP-1alpha and surface expression of ICAM-1 were significantly increased compared with non-activated platelets. The present study shows that activated platelets may contribute to expression of various inflammatory mediators on endothelial cells.

Activación plaquetaria por trombina / Platelet activation by thrombin

Cuando un agonista se une a su receptor específico sobre la membrana plaquetaria se inician una serie de cambios morfológicosy metabólicos que llevan al cambio de forma, agregación y secreción de contenidos granulares. La trombina, serinoproteasa multifuncional y fuerte agonosta plaquetario, tiene dos tipos de receptores sobre la membrana plaquetaria: de alta y de moderada afinidad. Este último pertenece a la familia de receptores ß2 adrenérgicos que presentan siete dominios de intramembrana, e inician la activación a través de G proteínas específicas. De esta manera se desencadenan diversos pasos metabólicos a través de varias enzimas claves. La actividad de la fosfolipasa Cß (PLCß) origina dos segundos mensajeros: Inositol 3 fosfato (IP3) que promueve la movilización de calcio del sistema tubular denso al citosol y el diacilglicerol (DG) que activa proteína quinasa C (PKC). Si bien la plaqueta no prolifera se han detectado enzimas relacionadas a oncogenes. De esta manera se han estudiado y comprendido nuevos caminos de activación. La familia de la tirosina quinasas, relacionas a la proliferación celular y oncogenes, fosforilan residuos tirosinas; en su mayoría son quinasas del tipo no receptor que se encuentran en el citosol como ser: Scr, Syk y FAK. La fosfolipasa Cy necesita la presencia de RasGAP, Rap 1b para hidrolizar fosfoinosítidos de membrana. La formación de este complejo trimérico se induce por trombina. La fosfoinositol-3-quinasa fosforila la posición 3 del anillo del inositol generando nuevos compuestos. La regulación completa de estos mecanismos de activación llevan a la respuesta hemostática plaquetaria. Su conocimiento hace posible el desarrollo de moléculas inhibitorias como terapéutica en los procesos trombóticos y tromboembólicos

Premio "Carlos Reussi" 1996: Modificaciones de la hemostasia en la hipertensión pulmonar primaria y secundaria / Prize \"Carlos Reussi\" 1996: Hemostasis modifications in the primary and secondary pulmonary hypertension

El endotelio vascular reacciona frente a diferentes estímulos fisiológicos y patológicos liberando diversas sustancias junto a marcadores de la coagulación y la fibrinólisis. La patología de la hipertensión pulmonar no está dilucidada y las diferencias entre la hipertensión primaria y secundaria es un límite que depende, seguramente, de los conocimientos fisiopatológicos y de las limitaciones de los métodos de diagnósticos. Los mecanismos de la coagulación y de la fibrinólisis pueden estar implicados en la etiología de la hipertensión pulmonar y el estudio de diversos marcadores relacionados con la hemostasia pueden orientar hacia la etiología de esta entidad nosológica. Para investigar el comportamiento del endotelio vascular en condiciones basales y luego de realizar la prueba de la oclusión venosa durante 20 minutos, se midieron varios marcadores en 22 pacientes con hipertensión pulmonar primaria (11 pacientes) o secundaria (11 pacientes) y se compararon con los hallados en 15 voluntarios sanos, sin antecedentes personales o familiares de tromboembolismo. En 16 de los pacientes se determinó además, la presión de la aurícula derecha y se la correlacionó con los valores de los marcadores de trombosis según la presión de la aurícula derecha estuviera por debajo o fuera mayor de 9 mmHg. Existe un déficit fibrinolítico en los pacientes con hipertensión primaria o secundaria demostrable por la prolongación del tiempo de lisis de las euglobulinas tanto en condiciones basales (pacientes 240ñ50 minutos; normales 171ñ58 minutos; p<0,001) como luego de la prueba de la oclusión venosa, luego de una estasis de 10 ó 20 minutos. Este defecto se debe en parte, a una disminución en la producción endotelial del activador tisular del plasminógeno (t-PA) que si bien no fue estadísticamente significativa en los valores basales, pudo observarse que su liberación fue menor a los 20 minutos de la estasis venosa (pacientes 34,4ñ21,2 ng/dl; normales 54,1ñ25,8 ng/dl; p<0,02). Pero el defecto fibrinolítico se debió principalmente a un aumento en la producción por el endotelio vascular, del inhibidor 1 del activador tisular del plasminógeno (PAI-1) (concentración plasmática en pacientes 59,8ñ22,3 AU/ml; en normales 30,3ñ14,5, p=0,05)...

Trombosis y neoplasia / Thrombosis and neoplasia

Se describe la relación entre distintos eventos trombóticos y la coexistencia de cáncer oculto o conocido. Se analizan los fenómenos protrombóticos involucrados en este tipo de pacientes y las alteraciones que se producen en el sistema de coagulación y de anticoagulación. Se analiza la ayuda del laboratorio y se comenta el tratamiento específico del episodio de trombosis en los cancerosos